Skip to main content

Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission

Abstract

Lung function impairment persists in 55% of critical COVID-19 patients three months after ICU discharge. Patient lung function, exercise capacity, radiologic, and quality of life data suggest impairment is related to radiologic lung involvement at admission.

To the editor

Acute respiratory distress syndrome (ARDS) is observed in 5% of COVID-19 patients and requires intensive care unit (ICU) admission. Regardless of the aetiology, ARDS survivors remain disabled and have increased rates of specialist use and re-admission to the hospital and ICU, as well as higher healthcare costs [1]. Cognitive impairment and quality of life (QoL) also remain severely impaired in long-term ARDS survivors [2]. Abnormal chest radiography and pulmonary function results persist years after discharge but tend to improve at 5 years [3].

As critical mid- and long-term sequelae associated with COVID-19 are not yet known, we aimed to assess lung function (Pulmonary function test (PFT) and respiratory muscle strength measurements), exercise capacity (6-min walking distance test (6MWDT)), dyspnoea (modified Medical Research Council (mMRC) dyspnoea scale), and QoL (Short Form 36 (SF-36)) in ARDS COVID-19 survivors, 3 months after ICU discharge. A non-contrast enhanced chest CT was also performed, in order to assess radiological changes between hospital admission and post-discharge period in terms of number of affected segments in both lungs (maximal score = 20), abnormalities distribution (peripheral/ central location, diffuse) and predominant pattern (ground glass opacities (GGO), consolidation, fibrosis).

Between 3 March and 2 June 2020, 63 patients were admitted to our ICU with a COVID-19 diagnosis confirmed by PCR and/or chest CT Scan. A total of 23 died (37%), and 22/33 ARDS survivors were included in this study. All included patients provided written informed consent to participate in the study. The study protocol was approved by the Saint-Pierre University Hospital ethics committee (AK/16–01-18/4613).

The mean age was 54.6 ± 10.9 years, 64% required mechanical ventilation (MV), and ICU length of stay was 20.7 ± 16.7 days. Extracorporeal membrane oxygenation use was required in 2 patients. Symptoms duration before hospital and ICU admission was respectively 7.7 ± 1.4 and 10.4 ± 2 days.

Demographics and clinical data are summarized in Tables 1, 2.

Table 1 Demographics and clinical data of COVID-19 patients admitted to ICU
Table 2 Lung function, dyspnea, quality of life, and chest CT assessments in COVID-19 patients 3 months after ICU discharge

PFT remained abnormal in 55% of patients, exhibiting restrictive pattern ± altered diffusing capacity of the lungs for carbon monoxide (DLCO). Sixty-five percent exhibited a 6MWDT below 80% and 52% were free from exertional dyspnoea according to mMRC scale. QoL (SF-36) was worse in the domains of "limitations due to physical health problems" and "limitations due to emotional problems".

All but 2 patients exhibited a decrease in affected segments on chest CT and 3/22 (14%) showed normalization. The majority of abnormalities were ground glass opacities at hospital admission and fibrosis 3 months later. Results are reported in Table 1, Fig. 1.

Fig. 1
figure1

Chest CT Scans of a critical COVID-19 patient, at admission, 14 days after symptoms onset (a) and 3-months post ICU discharge (b). Bilateral ground glass opacities (GGO) in a peripheral distribution are observed in both upper lobes on Pannel A. On Pannel B, GGO has disappeared, replaced by a discrete fibrosis area in the upper right lobe (black arrow)

On multivariate analysis, low total lung capacity was associated with the need for mechanical ventilation (p = 0.044) and low forced expiratory volume (FEV1) with high APACHE II score (p = 0.049). DLCO impairment, low FEV1, and number of affected segments on 3-month CT correlated with initial number of affected segments on chest CT scan (p < 0.0001, < 0.0001, and 0.01, respectively) but not with the initial radiologic pattern (GGO, consolidation, fibrosis). The use of glucocorticoids (GC) was associated with better outcomes in the above-mentioned parameters (p = 0.02, 0.008, and 0.04, respectively). In terms of demographic data, DLCO impairment and FEV1 were worse in males (p < 0.001 and 0.005).

Regarding QoL, low SF-36 values correlated with APACHE II (p = 0.026), MV (p = 0.05), MV duration (p = 0.0004), and ICU length of stay (p = 0.0002) (Fig. 2). The only predictor of fibrosis on 3-months chest CT scan among demographic and medical data was the presence of obstructive sleep apnoea (p < 0.001).

Fig. 2
figure2

Correlation between SF-36 and mechanical ventilation duration

This is the first report focusing on 3-months outcomes of critical COVID-19 survivors. Patients remained largely disabled 3 months after discharge in terms of lung function, exercise capacity, exertional dyspnoea, and QoL. Radiologic impairment was improved but normalization was only observed in a minority of patients.

Impaired DLCO has already been described as a common abnormality persisting after coronavirus infection. Indeed, SARS-CoV-2 looks like the two first coronavirus outbreaks in this regard (SARS CoV-1 in 2002 and MERS in 2012). In these patients, altered DLCO has been documented, with persisting significant impairment in DLCO in 24%-37% of survivors one year after illness onset [4]. More recently, in COVID-19 patients, DLCO impairment has been shown to be common and is observed in 39%-53% one month after discharge in hospitalized patients [5, 6] and in 16% 3 months after discharge [7]. We observed more decreased DLCO in our series, 45%, in line with the critical status of our patients. Indeed, in ARDS survivors, DLCO is the most often impaired lung functional marker, averaging 65% after 1 year [8]. A total of 27% of patients exhibited a restrictive pattern. This has been described in 12%-23% one month after discharge in COVID-19 hospitalized patients [5, 6].

As in other series, we observed a correlation between initial chest CT scan involvement and impaired PFT [5]. Previously, in SARS CoV-1, correlations between persistent chest X-ray abnormalities and impaired PFT were observed [9].

Regarding initial chest CT abnormalities, the different observed patterns can be explained by the delay between symptom onset and hospital admission. Indeed, GGO occurs generally since the beginning of COVID-19 and tends to decrease after 14 days. Consolidations appear around day 9 and fibrosis after day 14 [10, 11]. However, the severity of the disease seems rather related to the extent of lesions on initial chest CT than to the type of abnormalities [12, 13]. In the present study, we have shown that 3-months radiological and functional sequelae were related to initial disease extension on chest CT. Currently, there are no similar available reports.

With the generalisation of GC use, one can suppose that long-term recovery should be better, even in patients with severe radiological disease at admission. Indeed, in our series, better functional and radiologic outcomes were associated with GC use. At the time of hospitalization of our patients, GC use was controversial and not routinely advised. We have, however, administered GC to 7 patients in the context of persistent/refractory moderate-to-severe ARDS. Since this period, knowledge about COVID-19 has evolved with the publication of the RECOVERY study, highlighting mortality reductions associated with the use of GC in severe COVID-19 patients [14]. What we have observed in our series confirms the benefit of this treatment.

We have observed that obstructive sleep apnoea (SAOS) was a predictor of fibrosis on 3-months chest CT scan, although both patients were efficiently treated. It has been reported that SAOS is very prevalent in idiopathic lung fibrosis, and could induce fibrotic lesions through pleural pressure swings related to repeated upper airways collapse. These pressure swings lead to tractional microinjury of the alveoli, inducing further epithelial cells activation and fibroblast recruitment, favouring lung fibrosis [15].

Male sex was associated with worse PFT. This is not surprising as male sex has been established as a risk factor for developing ARDS, and thus a factor of disease severity, in a large Chinese series [16].

Exercise capacity, measured by 6MWDT, was still poor 3 months after ICU discharge and is probably multifactorial, according to the pre-existing medical conditions of the patients (obesity, diabetes,..), that are usually associated with decreased exercise capacity. We were not able to identify ICU parameters that predicted this impairment. In hospitalized SARS-CoV-1 patients, Ahmed et al. showed that 6MWDT was reduced at 3 months and slowly improved up to 12 months [17]. This disability was expected as critical illness can have important effects on the neuromuscular system. Acute lung injury survivors generally take 12 months to recover from physical complications [18]. However, maximum inspiratory pressure (MIP) was 82% 3 months after ICU discharge. This is much better than what was described in previous large series of patients experiencing prolonged MV, where MIP was 53% at discharge and increased to 68% 6 months later [19]. In a small, severe COVID-19 series assessed 30 days after discharge, the mean MIP was 80% [5], suggesting that recovery of respiratory muscle strength could be faster in COVID-19 than in other causes of acute respiratory failure. Of note, recovery was good in our patients despite the fact that half of them was suffering from obesity, which alters respiratory muscle strength.

Decreased QoL was associated with severity parameters in the ICU. This concerned mainly physical and emotional limitations, more than mental status, vitality, or pain. The same was observed in SARS-CoV-1 survivors, where lower SF-36 values were observed compared to healthy individuals and chronic disease patients at 6 months, similarly in the domains of physical and emotional health [17]. In addition to physical disability, ICU survivors commonly experience long-term mental health impairments. Post-traumatic stress disorder is present in 23% and persists for up to 5 years [20, 21]. Similar features were described in SARS-CoV-1 survivors [4]. Supplemental factors for altered emotional well-being included reduced access to family members during ICU stay, isolation, and fear of infecting others.

Limitations of the study

The small size of the study is a limiting factor to generalize the present results, but it is partly counter-balanced by the homogeneity of the studied population.

To conclude, the majority of critical COVID-19 survivors are still disabled 3 months after ICU discharge and the severity of the sequelae are related to ICU disease severity score (APACHE II) and admission chest CT abnormalities. However, some patients have already completely recovered, providing hope that few of the critical COVID-19 survivors will experience long-term sequelae.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.

    Herridge MS. Fifty years of research in ARDS. Long-term follow-up after acute respiratory distress syndrome. Insights for managing medical complexity after critical illness. Am J Respir Crit Care Med. 2017;196:1380–4.

    Article  Google Scholar 

  2. 2.

    Mikkelsen ME, Shull WH, Biester RC, Taichman DB, Lynch S, Demissie E, Hansen-Flaschen J, Christie JD. Cognitive, mood and quality of life impairments in a select population of ARDS survivors. Respirology. 2009;14:76–82.

    Article  Google Scholar 

  3. 3.

    Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, Kudlow P. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–304.

    CAS  Article  Google Scholar 

  4. 4.

    Hui DS, Wong KT, Ko FW, Tam LS, Chan DP, Woo J, Sung JJ. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest. 2005;128:2247–61.

    Article  Google Scholar 

  5. 5.

    Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, Zhou X, Liu X, Huang X, Yuan S, Chen C, Gao F, Huang J, Shan H, Liu J. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21:163.

    CAS  Article  Google Scholar 

  6. 6.

    Frija-Masson J, Debray MP, Gilbert M, Lescure FX, Travert F, Borie R, Khalil A, Crestani B, d’Ortho MP, Bancal C. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J. 2020;56:2001754.

    CAS  Article  Google Scholar 

  7. 7.

    Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, Jia JL, Li LM, Mao HL, Zhou XM, Luo H, Gao YF, Xu AG. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. https://doi.org/10.1016/j.eclinm.2020.100463.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Orme J Jr, Romney JS, Hopkins RO, Pope D, Chan KJ, Thomsen G, Weaver LK. Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome. Am J Resp Crit Care Med. 2003;167:690–4.

    Article  Google Scholar 

  9. 9.

    Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW, Chan MC, Chan DP, Tong MW, Rainer TH, Ahuja AT, Cockram CS, Sung JJ. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–9.

    CAS  Article  Google Scholar 

  10. 10.

    Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020;295(3):715–21. https://doi.org/10.1148/radiol.2020200370.

    Article  PubMed  Google Scholar 

  11. 11.

    Kwee TC, Kwee RM. Chest CT in COVID-19: What the Radiologist Needs to Know. Radiographics. 2020;40(7):1848–65. https://doi.org/10.1148/rg.2020200159.

    Article  PubMed  Google Scholar 

  12. 12.

    Ruch Y, Kaeuffer C, Ohana M, Labani A, Fabacher T, Bilbault P, Kepka S, Solis M, Greigert V, Lefebvre N, Hansmann Y, Danion F. CT lung lesions as predictors of early death or ICU admission in COVID-19 patients. Clin Microbiol Infect. 2020;26(10):1417–1417. https://doi.org/10.1016/j.cmi.2020.07.030.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Chon Y, Kim JY, Suh YJ, Lee JY, Park JS, Moon SM, Lee MS, Yi J. Adverse Initial CT Findings Associated with Poor Prognosis of Coronavirus Disease. J Korean Med Sci. 2020;35(34):e316. https://doi.org/10.3346/jkms.2020.35.e316.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep. 2018;7(4):118–25. https://doi.org/10.1007/s13665-018-0210-7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan. China JAMA Intern Med. 2020;180:934–43.

    CAS  Article  Google Scholar 

  17. 17.

    Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, Eyre L, Breen A, O’Connor R, Jones A, Sivan M. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med. 2020;52:63.

    Google Scholar 

  18. 18.

    Ahmed H, Patel K, Greenwood D, Halpin S, Lewthwaite P, Salawu A, Sivan M. Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or icu admission: a systematic review and meta-analysis of follow-up studies. MedRxiv. 2020;9:99.

    Google Scholar 

  19. 19.

    Fan E, Dowdy DW, Colantuoni E, Mendez-Tellez PA, Sevransky JE, Shanholtz C, Himmelfarb CR, Desai SV, Ciesla N, Herridge MS, Pronovost PJ, Needham DM. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. Crit Care Med. 2014;42:849–59.

    Article  Google Scholar 

  20. 20.

    Jubran A, Grant BJB, Duffner LA, Collins EG, Lanuza DM, Hoffman LA, Tobin MJ. Long-term outcome after prolonged mechanical ventilation a long-term acute-care hospital study. Am J Respir Crit Care Med. 2019;199:1508–16.

    Article  Google Scholar 

  21. 21.

    Bienvenu OJ, Friedman LA, Colantuoni E, Dinglas VD, Sepulveda KA, Mendez-Tellez P, Shanholz C, Pronovost PJ, Needham DM. Psychiatric symptoms after acute respiratory distress syndrome: a 5-year longitudinal study. Intensive Care Med. 2018;44:38–47.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the contribution of a medical writer, Sandy Field, PhD, for editing of this manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Contributions

LT, LD, AR, NDV, MB collected the data; LT, SA, AVB, MB performed data analyses and prepared the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Marie Bruyneel.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the Saint-Pierre University Hospital ethics committee (AK/16–01-18/4613).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Truffaut, L., Demey, L., Bruyneel, A.V. et al. Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res 22, 29 (2021). https://doi.org/10.1186/s12931-021-01625-y

Download citation